Molecular Imaging Clinical Trial
Official title:
Targeted Molecular Imaging of [68Ga]- Labelling Anti-IGF-1R Affibody Molecule in IGF-1R Overexpression Cancer Patients （Such as Colon Cancer、NSCLC and Gliomas）and Healthy Volunteers
The investigators developed [68Ga]-labelling Anti-IGF-1R Affibody Molecule as a targeted molecular imaging agent for noninvasive and repeatable detecting IGF-1R expression status.
The goals of investigators are to evaluate the use of [68Ga]-labelling Anti-IGF-1R Affibody Molecule as a novel PET/CT radiotracer to monitor IGF-1R expression status. The investigators want to evaluate the use of [68Ga]-labelling Anti-IGF-1R Affibody Molecule in IGF-1R expression cancer imaging in adult cancer patients （colon cancer 、NSCLC、gliomas cancer patients）with different IGF-1R expression status. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02916329 -
In Vivo EGFR-ECD Molecular Imaging Using [68Ga]- Labelling Anti-EGFR Affibody Molecule
|
N/A | |
| Completed |
NCT01944215 -
Evaluation of the Effect of Fasting and Exercise on Uptake of Tc-99m Sestamibi in Breast Tissue
|
Phase 1 | |
| Active, not recruiting |
NCT03358589 -
Molecular Evaluation in Metastatic Breast Cancer
|
N/A | |
| Completed |
NCT03031522 -
EGFR Molecular Classification In Vivo
|
N/A | |
| Recruiting |
NCT02717221 -
In Vivo EGFR Molecular Classification and Treatment Response
|
N/A | |
| Completed |
NCT03233243 -
Rosuvastatin Effect on Atherosclerotic Plaque Metabolism
|
Phase 4 | |
| Completed |
NCT02323217 -
I2PETHV - Imidazoline2 Binding Site in Healthy Volunteers
|
Early Phase 1 | |
| Enrolling by invitation |
NCT05575765 -
Clinical Validation of Multimodal Digestive Endoscopy
|